Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) – 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Carsten Utoft Niemann, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J Veldhuis, Rogier Mous, Clemens Mellink, Johan A Dobber, Christian Bjørn Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C Dompeling, Juha Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa T Tran, Kazem Nasserinejad, Mark-David Levin, Arnon P. Kater

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

OriginalsprogEngelsk
Publikationsdato9. dec. 2019
StatusUdgivet - 9. dec. 2019
BegivenhedAmerican Society of Hematology: 61st Annual Meeting (ASH) - Orlando, USA
Varighed: 7. dec. 201910. dec. 2019

Konference

KonferenceAmerican Society of Hematology: 61st Annual Meeting (ASH)
LandUSA
ByOrlando
Periode07/12/201910/12/2019

Citationsformater

Niemann, C. U., Dubois, J., Kersting, S., Enggaard, L., Veldhuis, G. J., Mous, R., Mellink, C., Dobber, J. A., Poulsen, C. B., Frederiksen, H., Janssens, A., Schjødt, I., Dompeling, E. C., Juha Ranti, J., Mattsson, M., Bellido, M., Tran, H. T., Nasserinejad, K., Levin, M-D., & Kater, A. P. (2019). Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) – 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial. Poster session præsenteret på American Society of Hematology: 61st Annual Meeting (ASH), Orlando, USA. https://ashpublications.org/blood/article/134/Supplement_1/4292/425636/Venetoclax-and-Ibrutinib-for-Patients-with